HC Wainwright Has Bearish Forecast for BioNTech Q3 Earnings

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) - Investment analysts at HC Wainwright lowered their Q3 2025 earnings per share (EPS) estimates for BioNTech in a research report issued to clients and investors on Wednesday, June 25th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($1.12) per share for the quarter, down from their prior estimate of ($1.10). HC Wainwright has a "Buy" rating and a $138.00 price objective on the stock. The consensus estimate for BioNTech's current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for BioNTech's Q1 2026 earnings at ($2.24) EPS, Q2 2026 earnings at ($2.27) EPS and FY2026 earnings at ($4.32) EPS.

BNTX has been the subject of a number of other research reports. Leerink Partners set a $112.00 target price on shares of BioNTech in a research note on Monday, June 2nd. Morgan Stanley decreased their target price on BioNTech from $140.00 to $132.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 6th. Truist Financial reiterated a "buy" rating and set a $155.00 price target (up from $151.00) on shares of BioNTech in a research report on Tuesday, June 3rd. Canaccord Genuity Group restated a "buy" rating and issued a $171.44 price objective on shares of BioNTech in a report on Tuesday, March 11th. Finally, Citigroup reaffirmed a "buy" rating and set a $140.00 target price (down previously from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $137.86.

BioNTech Price Performance

NASDAQ BNTX traded up $0.58 on Friday, hitting $106.72. The company had a trading volume of 490,569 shares, compared to its average volume of 943,452. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.18 and a quick ratio of 10.02. The company's fifty day moving average price is $102.79 and its 200-day moving average price is $107.14. The company has a market capitalization of $25.65 billion, a PE ratio of -31.39 and a beta of 1.29. BioNTech has a 12-month low of $76.53 and a 12-month high of $131.49.

Institutional Trading of BioNTech

A number of hedge funds and other institutional investors have recently modified their holdings of BNTX. Bank of New York Mellon Corp increased its position in shares of BioNTech by 4.3% during the fourth quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock valued at $419,000 after acquiring an additional 150 shares during the last quarter. QRG Capital Management Inc. acquired a new stake in BioNTech in the 4th quarter valued at approximately $275,000. SVB Wealth LLC acquired a new stake in BioNTech in the 4th quarter valued at approximately $204,000. Jones Financial Companies Lllp raised its position in BioNTech by 110.3% in the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock valued at $53,000 after purchasing an additional 246 shares during the period. Finally, SBI Securities Co. Ltd. acquired a new position in BioNTech during the fourth quarter worth $391,000. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.